Vidya Announces Completion of Study on Akkermansia Probiotic

Vidya, a supplier specializing in botanicals and microbiome products, announced the completion of a human clinical study on supplementation of its Akkermansia muciniphila ingredient, NūGensia. The study, which measured results of a daily dose of 5 billion colony-forming units (CFU), awaits publication, and additional clinical trials on daily supplementation with 7 billion and 10 billion CFU dosages are currently underway, the company reported.

The study demonstrated that supplementation with live, stable Akkermansia helps to restore regularity, support measures of gut health, and improve abdominal discomfort and bloating. The results also showed measurable improvements in bowel frequency, stool consistency, and gut barrier integrity, along with self-reported results in a digestive-related quality of life assessment, such as reduced stress, better sleep, and enhanced emotional well-being.

” NūGensia is the first 5 billion CFU live stable Akkermansia muciniphila to clinically validate this level of multi-dimensional gut health support,” said Subhendu Nayak, director of R&D for probiotics at Vidya. “This human clinical trial confirms what we’ve long believed: Akkermansia is a keystone next generation probiotic strain, but only if you can deliver it alive, in the right dose, and in a stable, effective format.”

NūGensia relies on a unique delivery system which uses a starch-based protective shell to shield the live Akkermansia muciniphila strain from oxygen exposure during production and storage, a critical challenge that has long limited the viability and commercial potential of this bacterial strain as a dietary supplement ingredient.

“The market is flooded by Akkermansia products labeled with AFU or TFU enumeration only. Consumers are unaware of the important differences between enumeration methods. CFU remains the gold standard for live and viable strains,” said Thomas Guilliams, PhD, senior scientific advisor at Vidya. The company verifies live counts via CFU measurements in every batch, it reported.